European Journal of Cancer
Volume 45, Issue 1 , Pages 146-153 , January 2009

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma

  • J. Sadones

      Affiliations

    • Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    • ,
  • A. Michotte

      Affiliations

    • Experimental Pathology and Neuropathology, UZ Brussel, Laarbeeklaan 101, B1090 Brussels, Belgium
    • ,
  • P. Veld

      Affiliations

    • Experimental Pathology and Neuropathology, UZ Brussel, Laarbeeklaan 101, B1090 Brussels, Belgium
    • ,
  • C. Chaskis

      Affiliations

    • Neurosurgery, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    • ,
  • R. Sciot

      Affiliations

    • Pathology, Universitair Ziekenhuis Leuven, Campus Sint-Rafael, Minderbroedersstraat 12, B-3000 Leuven, Belgium
    • ,
  • J. Menten

      Affiliations

    • Radiotherapy-Oncology, Universitair Ziekenhuis Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    • ,
  • E.J.R. Joossens

      Affiliations

    • Medical Oncology, Ziekenhuis Netwerk Middelheim, Lindendreef 1, 2020 Antwerp, Belgium
    • ,
  • T. Strauven

      Affiliations

    • Neurology, AZ St.-Augustinus, Oosterveldlaan 24, 2610 Antwerp, Belgium
    • ,
  • L.A. D’Hondt

      Affiliations

    • Medical Oncology, Centre Hospitalier Notre-Dame et Reine Fabiola, Grand’Rue 3, 6000 Charleroi, Belgium
    • ,
  • D. Sartenaer

      Affiliations

    • Département de Génétique, Institut de Pathologie et de Génétique, Avenue Georges Lemaitre 25, 6041 Gosselies, Belgium
    • ,
  • S.F.E.H. Califice

      Affiliations

    • OncoMethylome Sciences SA, Tour 5 GIGA (B34), +3, Avenue de l’Hopital 11, B-4000 Liège, Belgium
    • ,
  • K. Bierau

      Affiliations

    • OncoMethylome Sciences SA, Tour 5 GIGA (B34), +3, Avenue de l’Hopital 11, B-4000 Liège, Belgium
    • ,
  • C. Svensson

      Affiliations

    • OncoMethylome Sciences SA, Tour 5 GIGA (B34), +3, Avenue de l’Hopital 11, B-4000 Liège, Belgium
    • ,
  • J. De Grève

      Affiliations

    • Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    • ,
  • B. Neyns

      Affiliations

    • Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
    • Corresponding Author InformationCorresponding author: Tel.: +32 2 477 64 15; fax: +32 2 477 62 10.

Received 20 June 2008 ,Revised 15 August 2008 ,Accepted 5 September 2008.

References 

  1. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852–9861
  2. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol. 2006;24:2707–2714
  3. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol. 2006;24:2715–2722
  4. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncol. 2007;9:271–279
  5. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol (Berl). 2003;106:479–485
  6. Watanabe T, Katayama Y, Yoshino A, et al. Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 2007;17:5–10
  7. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167–223
  8. Damia G, D’Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer. 2007;43:1791–1801
  9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med. 2000;343:1350–1354
  10. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689–4692
  11. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352:997–1003
  12. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933–4938
  13. Everhard S, Kaloshi G, Criniere E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006;60:740–743
  14. Califice S, Diserens A-C, Di Stefano I, et al. Comparison of gel-based MSP and real-time fluorescence-based MSP to determine the methylation status of the MGMT gene promoter in glioblastoma samples [abstract]. Presented at: MGMT 2005, August 6–9, 2005, Keele, UK; 2005.
  15. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10:332–337
  16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987–996
  17. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol. 2006;24:4412–4417
  18. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259–266
  19. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Brit J Cancer. 2000;83:588–593
  20. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762–2771
  21. Brandes AA, Ermani M, Basso U, et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2001;12:255–257
  22. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Brit J Cancer. 2003;88:1004–1011
  23. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Brit J Cancer. 2006;95:1155–1160
  24. Neyns B, Chaskis C, Joosens E, et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest. 2008;26:269–277
  25. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–3361
  26. Everaert E, Neyns B, Joosens E. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol. 2004;70:37–48
  27. Neyns B, Everaert E, Joosens E, Strauven T, Branle F, Menten J. Temozolomide for the treatment of recurrent glioma: results of a compassionate use program in Belgium. J Clin Oncol. 2004;23(Suppl.):117;[Abstract 1541]
  28. Maxwell JA, Johnson SP, Quinn JA, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther. 2006;5:2531–2539
  29. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871–1874
  30. Ishii D, Natsume A, Wakabayashi T, et al. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo). 2007;47:341–349[discussion 350]
  31. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–710
  32. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25:2601–2606
  33. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288–2294

PII: S0959-8049(08)00701-6

doi: 10.1016/j.ejca.2008.09.002

European Journal of Cancer
Volume 45, Issue 1 , Pages 146-153 , January 2009

Article Tools

* Image Usage & Resolution